TargetMol

pyridostigmine

Product Code:
 
TAR-T8631
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T8631-1mg1mg£177.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-2mg2mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-1mL1 mL * 10 mM (in DMSO)£298.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-5mg5mg£310.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-10mg10mg£434.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-25mg25mg£670.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-50mg50mg£914.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T8631-100mg100mg£1,211.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Pyridostigmine is an acetylcholinesterase inhibitor that can treat myasthenia gravis by increasing acetylcholine at the postsynaptic motor endplate.
CAS:
155-97-5
Formula:
C9H13BrN2O2
Molecular Weight:
261.116
Purity:
0.9985
SMILES:
C[N+]1=CC=CC(=C1)OC(=O)N(C)C

References

Byun J I , Moon J , Kim D Y , et al. Efficacy of single or combined midodrine and pyridostigmine in orthostatic hypotension[J]. Neurology, 2017:10.1212/WNL.0000000000004340. Ahuja N K , Mische L , Clarke J O , et al. Pyridostigmine for the treatment of gastrointestinal symptoms in systemic sclerosis[J]. Semin Arthritis Rheum, 2018:S0049017217305498.